Adaptimmune Therapeutics share price logo

Adaptimmune Therapeutics

OTC: ADAPY

$0.03

+0.01

(+20.00%)

Live

as on

Adaptimmune Therapeutics Stock Performance

as on October 24, 2026 at 6:35 am IST

  • $0.03
    $0.03

  • 52 Week's Low

    52 Week's High

    downward going graph

    100.00%

    Downside

    -100.00%

    Upside

    downward going graph

Adaptimmune Therapeutics share price movements today

Previous Close
$0.03
Open
$0.03
Volume
292.4K
Market Cap
$8.5M
Day's Low - High
$0.03 - $0.03

Adaptimmune Therapeutics Historical Returns

1 Month Return
-3.85 %
3 Month Return
-25.6 %
1 Year Return
0 %
3 Year Return
0 %
5 Year Return
0 %

Adaptimmune Therapeutics Stock Fundamentals & Key Indicators

Check Adaptimmune Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$8.5M

EPS (TTM)

-0.669

Dividend Yield

0.00%

PE Ratio (TTM)

-0.09

Industry PE ratio

-4.13

PEG Ratio

0.00

Return On Equity TTM

115.05%

Adaptimmune Therapeutics stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Adaptimmune Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Adaptimmune Therapeutics image
Adaptimmune Therapeutics
NA$8.5MNA-0.09100.00%0.00%

Indian Investors' Interest in Adaptimmune Therapeutics Stock

Search interest for Adaptimmune Therapeutics Stock has increased by 827% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:827% versus previous 30 day period

Adaptimmune Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
47
5
7
0
5
128
40
3
7
13
Gross Profit
45
2
4
-2
2
125
40
3
6
11
Operating Income
1
-44
-46
-54
-49
68
-14
-73
-45
-30
EBITDA
-1
-18
-43
-49
-46
71
-12
-67
-42
-26
Interest Expense
-
-
-
-
-
0
1
1
1
0
Depreciation
1
2
2
2
2
2
2
2
2
2
Income Before Tax
1
-20
-44
-52
-47
67
-16
-70
-47
-29
Income Tax Expense
0
0
0
-4
0
-1
0
-1
0
0
Net Income
1
-21
-45
-48
-48
69
-17
-74
-47
-30
Net Profit Margin
96.09%
56.35%
60.72%
-1133.77%
50.19%
97.97%
100.00%
100.00%
87.93%
81.71%

Adaptimmune Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
37
59
1
3
6
27
60
178
Gross Profit
37
59
-96
-87
-104
-100
50
177
Operating Income
-80
-82
-139
-133
-162
-163
-138
-68
EBITDA
-75
-74
-131
-125
-155
-155
-128
-52
Interest Expense
-
-
-
-
-
-
-
3
Depreciation
5
7
8
7
6
6
9
11
Income Before Tax
-69
-95
-136
-129
-157
-162
-112
-67
Income Tax Expense
0
0
0
0
0
2
1
3
Net Income
-70
-95
-137
-130
-158
-165
-113
-70
Net Profit Margin
100.00%
100.00%
-8589.93%
-2213.49%
-1706.64%
-370.48%
83.65%
99.96%

Adaptimmune Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
1
-21
-45
-47
-48
69
-17
-70
-47
-30
Operating Cash Flow
-37
-43
-45
-14
-31
47
-54
-34
-66
-34
Investing Cash Flow
48
2
57
68
0
0
-66
8
41
18
Financing Cash Flow
0
0
0
0
29
24
25
0
-25
1
Change in Cash
11
-41
12
53
-3
71
-95
-26
-50
-15

Adaptimmune Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-70
-95
-137
-130
-158
-165
-113
-70
Operating Cash Flow
-54
-104
-112
-53
10
-141
-140
-73
Investing Cash Flow
-126
-17
94
-278
75
89
176
-58
Financing Cash Flow
103
102
0
340
3
12
0
78
Change in Cash
-74
-15
-17
6
90
-42
37
-53

Global Institutional Holdings in Adaptimmune Therapeutics

Check out the Institutions with significant holdings in Adaptimmune Therapeutics.

Funds
Holdings
Fidelity Commonwealth Trust II
0.04%
LoCorr Investment Trust
0.01%
Baillie Gifford Funds
0.00%
HARBOR FUNDS
0.00%

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.
OrganisationAdaptimmune Therapeutics
HeadquartersThe Innovation Centre, Abingdon, OXF, OX14 4RY, GB
IndustryBiotechnology
CEOChristopher James Hill

Key Management of Adaptimmune Therapeutics

Name

Title

Mr. Christopher James Hill ACA, BA (Hons)

CEO, CFO, Secretary & Director

Dr. Helen Katrina Tayton-Martin MBA, Ph.D.

Co-Founder

Dr. Juli P. Miller Ph.D.

VP of Corporate Affairs & Investor Relations

Ms. Dana Lynch

Senior Director of Corporate Communications

Ms. Kimberly Freeman

Vice President of Commercial Planning

Laura Gunn

Vice President of Medical Affairs

FAQs

What is Adaptimmune Therapeutics share price today?

Adaptimmune Therapeutics share price today is $0.03 as on . Adaptimmune Therapeutics share today touched a day high of $0.03 and a low of $0.03.

What is the 52 week high and 52 week low for Adaptimmune Therapeutics share?

Adaptimmune Therapeutics share touched a 52 week high of $0.00 on and a 52 week low of $0.00 on . Adaptimmune Therapeutics stock price today i.e. is trending at $0.03,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Adaptimmune Therapeutics's market capitalisation today?

Adaptimmune Therapeutics market capitalisation is $0.00T as on .

How to invest in Adaptimmune Therapeutics Stock (ADAPY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Adaptimmune Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Adaptimmune Therapeutics Stock (ADAPY) from India?

Indian investors can start investing in Adaptimmune Therapeutics (ADAPY) shares with as little as ₹94.94000244140625 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.40 in Adaptimmune Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Adaptimmune Therapeutics share’s latest price of $0.03 as on October 24, 2026 at 1:05 am IST, you will get 333.3333 shares of Adaptimmune Therapeutics. Learn more about fractional shares .